CAZZANIGA GIOVANNI
Biography
EDUCATION
2021 - Associate Professor, Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2018 - Assistant Professor (Ricercatore a Tempo Determinato di tipo B, RTDB), Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2014 - Qualification (National Scientific Habilitation, ASN) for Associate Professorship to the following sections: 05/F1 Applied Biology BIO/13 and 06/A1 Medical Genetics MED/03, 06/A2 General and Clinical Pathology (deadline 07/01/2023).
2004 - Specialist in Medical Genetics. Faculty of Medicine, University of Milan, Italy. 70/70 cum laude.
1992 - Specialist in Pharmaceutical Research at the “M.Negri” Pharmacology Research Institute of Milan, Italy.
1990 - Biological Science degree at the University of Milan, Italy. 110/110 cum laude.
PROFESSIONAL POSITION
05/2023 - now: Acting Director (ff), Medical Genetics, Foundation IRCCS San Gerardo dei Tintori, Monza, Italy
03/2023 - now: Deputy Director, Ph.D. Program in Translational and Molecular Medicine (Dimet), University of Milan Bicocca.
12/2021 - now: Associate Professor, Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2006 - now: Head, “Molecular genetics of leukemia” Unit, Centro Tettamanti, Fondazione Tettamanti, Monza, Italy.
2018-2021: Assistant Professor (Ricercatore a Tempo Determinato di tipo B, RTDB), Medical Genetics, School of Medicine and Surgery, Univ. Milan Bicocca.
2009 - 04/2023: Director, Laboratory of Hemato-Oncology Diagnostics “M. Tettamanti”, Fondazione MBBM, Monza.
1995/1997: Research fellow at the “M.Tettamanti” Research Center, Pediatric Clinic, University of Milan-Bicocca, Ospedale San Gerardo, Monza, Italy.
1990/1994: Research fellow at the Laboratory of Enzymology - Molecular Biology Unit - "M.Negri" Pharmacology Research Institute, Milan, Italy.
Research
MAJOR RESEARCH INTERESTS
- Genetic predisposition to childhood acute lymphoblastic leukemia (ALL)
- Prenatal origin of ALL
- Molecular characterization of childhood ALL
- Functional analysis of genetic aberrations in leukemic patients (PAX5 lesions, Ph-like ALL, Down Syndrome ALL, MLL-rearrangements) and in vitro/in vivo drug targeting
- Minimal residual disease monitoring in childhood ALL, by analysis of T-cell Receptor and Immunoglobulin genes’ rearrangements.
Publications
Saettini, F., Guerra, F., Mauri, M., Salter, C., Adam, M., Adams, D., et al. (2025). Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia. JOURNAL OF CLINICAL IMMUNOLOGY, 45(1) [10.1007/s10875-024-01793-8]. Detail
Conter, V., Valsecchi, M., Cario, G., Zimmermann, M., Attarbaschi, A., Stary, J., et al. (2024). Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. JOURNAL OF CLINICAL ONCOLOGY, 42(8), 915-926 [10.1200/JCO.23.01388]. Detail
Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD, 143(14), 1399-1413 [10.1182/blood.2023021349]. Detail
Villa, N., Redaelli, S., Farina, S., Sala, E., Crosti, F., Cozzolino, S., et al. (2024). Cytogenetically Balanced Reciprocal Translocation Could Hide Molecular Genomic Unbalances: Implications for Foetal Phenotype Correlation. DIAGNOSTICS, 14(16) [10.3390/diagnostics14161732]. Detail
Bettini, L., Fazio, G., Saitta, C., Piazza, R., Palamini, S., Buracchi, C., et al. (2024). Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation. LEUKEMIA [10.1038/s41375-024-02399-0]. Detail